Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
Allergic Conjunctivitis
Primary: Ocular Itching at Day 7 (7 Minutes Post Conjunctival Allergen Challenge [CAC 6]) — 2.65; 2.68; 3.07; 2.88 units on a scale — p=0.3235
N/A N=180 Intravenous Alcohol Administration Using BrAc Method in Healthy Subjects With and Without a Family History of Alcoholism
Alcoholism
Primary: Number of Drinks Felt Consumed at Baseline — 0; 0; 0; 0 drinks felt consumed
Phase 2 N=52 Varenicline for Methamphetamine Dependence
Methamphetamine Dependence · Substance Abuse · Methamphetamine Abuse
Primary: End of Treatment Abstinence — 5; 4 Participants
Phase 3 N=718 A Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
Dry Eye Disease
Primary: Change From Baseline in Inferior Corneal Fluorescein Staining Score to Day 84 — 2.39; 2.40; -0.73; -0.71 units on a scale — p=0.6186
Phase 3 N=588 Safety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
Keratoconjunctivitis Sicca · Dry Eye Disease
Primary: Ocular Sign: Change From Baseline in Inferior Corneal Fluorescein Staining to Day 84 — -0.07; 0.17 units on a scale — p=0.0007
Phase 1 N=18 A Food-Drug Interaction Study of Serum Urate After Oral Inosine
Healthy
Primary: Cmax: Maximum Observed Serum Urate Concentration — 6.6; 6.4 mg/dL
Phase 2 N=85 Does More Practice Improve Arm Movement After Stroke?
Stroke
Primary: Change in Action Research Arm Test (ARAT) Score Per Week — 0.4; -0.05; 0.31; 0.66 change in units on a scale/week — p=.01
Early Phase 1 N=12 TOPIC Trial for COPD
Chronic Obstructive Pulmonary Disease
Primary: Change in COPD as Measured by the Sweat Analysis in Each Group — -8.0; 2.0 mmol/L
Phase 2 N=13 Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Cancer
Primary: Response Rate — 1; 2; 4 participants
N/A N=151 Randomized Evaluation of Maxillary Antrostomy Versus Ostial Dilation Efficacy Through Long-Term Follow-Up
Chronic Sinusitis
Primary: Sinus Symptom Improvement — -1.59; -1.60; 0.88; 0.88 units on a scale — p=<0.001
N/A N=10 Evaluation of Propranolol's Effect on Pain and Inflammation.
Pain Measurement
Primary: Change From Baseline in Heat Pain Threshold During Infusion in Non-Inflamed Skin — 1.01; 0.14; 0.01 degree centigrade
Phase 3 N=57 Trial of Methyl B12 on Behavioral and Metabolic Measures in Children With Autism
Autistic Disorder
Primary: Clinical Global Impression-Improvement (CGI-I) — 3.1; 2.4 CGI- Improvement
Phase 4 N=338 Evaluation of Dalteparin for Long-term (One Year) Treatment of Blood Clots in Subjects With Cancer
Cancer
Primary: Number of Participants With Major Bleeding Events Adjudicated by Central Adjudication Committee — 14 participants
Phase 2 N=306 An Evaluation of Weekly Tafenoquine
Falciparum Parasitaemia
Primary: Prophylactic Outcome Defined by the Subject Having no Positive Smears — 93; 90; 92; 6 participants